Antineoplastic Agents, Phytogenic
Drug Screening Assays, Antitumor
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Tumor Cells, Cultured
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Dose-Response Relationship, Drug
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Antineoplastic Combined Chemotherapy Protocols
Drug Resistance, Neoplasm
Drug Evaluation, Preclinical
Xenograft Model Antitumor Assays
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Drug Administration Schedule
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Clinical Trials as Topic
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
A family of intracellular CYSTEINE ENDOPEPTIDASES that play a role in regulating INFLAMMATION and APOPTOSIS. They specifically cleave peptides at a CYSTEINE amino acid that follows an ASPARTIC ACID residue. Caspases are activated by proteolytic cleavage of a precursor form to yield large and small subunits that form the enzyme. Since the cleavage site within precursors matches the specificity of caspases, sequential activation of precursors by activated caspases can occur.
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
Phospholipids which have an alcohol moiety in ethereal linkage with a saturated or unsaturated aliphatic alcohol. They are usually derivatives of phosphoglycerols or phosphatidates. The other two alcohol groups of the glycerol backbone are usually in ester linkage. These compounds are widely distributed in animal tissues.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Reactive Oxygen Species
Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of signal transduction and gene expression, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS.
Coverings for the hands, usually with separations for the fingers, made of various materials, for protection against infections, toxic substances, extremes of hot and cold, radiations, water immersion, etc. The gloves may be worn by patients, care givers, housewives, laboratory and industrial workers, police, etc.
A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.
Inhibitory Concentration 50
Carcinoma, Ehrlich Tumor
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Tumor Stem Cell Assay
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Topoisomerase II Inhibitors
Drug Resistance, Multiple
Oncology Service, Hospital
A genotoxicological technique for measuring DNA damage in an individual cell using single-cell gel electrophoresis. Cell DNA fragments assume a "comet with tail" formation on electrophoresis and are detected with an image analysis system. Alkaline assay conditions facilitate sensitive detection of single-strand damage.
Nitrogen Mustard Compounds
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
DNA Topoisomerases, Type II
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Lethal Dose 50
Gene Expression Regulation, Neoplastic
Metabolic Detoxication, Drug
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
Mammary Neoplasms, Experimental
Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. (1/4985)Overexpression of the HER-2/neu proto-oncogene, which encodes the tyrosine kinase receptor p185neu, has been observed in tumors from breast cancer patients. We demonstrated previously that emodin, a tyrosine kinase inhibitor, suppresses tyrosine kinase activity in HER-2/neu-overexpressing breast cancer cells and preferentially represses transformation phenotypes of these cells in vitro. In the present study, we examined whether emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and whether emodin can sensitize these tumors to paclitaxel, a commonly used chemotherapeutic agent for breast cancer patients. We found that emodin significantly inhibited tumor growth and prolonged survival in mice bearing HER-2/neu-overexpressing human breast cancer cells. Furthermore, the combination of emodin and paclitaxel synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu-overexpressing breast cancer cells in vitro and synergistically inhibited tumor growth and prolonged survival in athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of p185neu. Both immunohistochemical staining and Western blot analysis showed that emodin decreases tyrosine phosphorylation of HER-2/neu in tumor tissue. Taken together, our results suggest that the tyrosine kinase activity of HER-2/neu is required for tumor growth and chemoresistance and that tyrosine kinase inhibitors such as emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and also sensitize these tumors to paclitaxel. The results may have important implications in chemotherapy for HER-2/neu-overexpressing breast tumors. (+info)
CLIP-170 highlights growing microtubule ends in vivo. (2/4985)A chimera with the green fluorescent protein (GFP) has been constructed to visualize the dynamic properties of the endosome-microtubule linker protein CLIP170 (GFP-CLIP170). GFP-CLIP170 binds in stretches along a subset of microtubule ends. These fluorescent stretches appear to move with the growing tips of microtubules at 0.15-0.4 microm/s, comparable to microtubule elongation in vivo. Analysis of speckles along dynamic GFP-CLIP170 stretches suggests that CLIP170 treadmills on growing microtubule ends, rather than being continuously transported toward these ends. Drugs affecting microtubule dynamics rapidly inhibit movement of GFP-CLIP170 dashes. We propose that GFP-CLIP170 highlights growing microtubule ends by specifically recognizing the structure of a segment of newly polymerized tubulin. (+info)
The topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecin. (3/4985)Camptothecin is an antitumor agent that kills cells by converting DNA topoisomerase I into a DNA-damaging poison. Although camptothecin derivatives are now being used to treat tumors in a variety of clinical protocols, the cellular factors that influence sensitivity to the drug are only beginning to be understood. We report here that two genes required for sister chromatid cohesion, TRF4 and MCD1/SCC1, are also required to repair camptothecin-mediated damage to DNA. The hypersensitivity to camptothecin in the trf4 mutant does not result from elevated expression of DNA topoisomerase I. We show that Trf4 is a nuclear protein whose expression is cell cycle-regulated at a post-transcriptional level. Suppression of camptothecin hypersensitivity in the trf4 mutant by gene overexpression resulted in the isolation of three genes: another member of the TRF4 gene family, TRF5, and two genes that may influence higher order chromosome structure, ZDS1 and ZDS2. We have isolated and sequenced two human TRF4 family members, hTRF4-1 and hTRF4-2. The hTRF4-1 gene maps to chromosome 5p15, a region of frequent copy number alteration in several tumor types. The evolutionary conservation of TRF4 suggests that it may also influence mammalian cell sensitivity to camptothecin. (+info)
Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. (4/4985)A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m(-2) and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m(-2), and the dose was escalated by an increase of 10 mg m(-2). The maximally tolerated dose of CPT-11 was determined as 60 mg m(-2) because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m(-2) and 60 mg m(-2) respectively. (+info)
A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. (5/4985)Clinically available taxanes represent one of the most promising class of antitumor agents, despite several problems with their solubility and toxicity. In an attempt to improve the pharmacological profile of taxanes, a new series of analogues was synthesized from 14beta-hydroxy-10-deacetylbaccatin III and tested in a panel of human tumor cell lines. On the basis of the pattern of cytotoxicity and lack of cross-resistance in tumor cell lines expressing the typical multidrug-resistant phenotype, a compound (IDN5109) was selected for preclinical development. A comparative efficacy study of IDN5109 and paclitaxel was performed using a large panel of human tumor xenografts, characterized by intrinsic (seven tumors) or acquired (four tumors) resistance to cisplatin or doxorubicin, including four ovarian, one breast, one cervical, three lung, one colon, and one prostatic carcinoma. Drugs were delivered i.v. according to the same schedule (four times every 4th day). IDN5109 achieved a very high level of activity (percentage tumor weight inhibition >70%; log10 cell kill >1) in all but one of the tested tumors. Compared to paclitaxel, IDN5109 exhibited a significantly superior activity in six tumors (including the four tumors that were resistant to paclitaxel) and a comparable activity against the other five paclitaxel-responsive tumors. Additional advantages of IDN5109 over paclitaxel were also suggested by its toxicity profile. IDN5109 was not only less toxic (maximal tolerated doses were 90 and 54 mg/kg for IDN5109 and paclitaxel, respectively), but it also appeared to be endowed with a reduced neurotoxic potential and an improved profile of tolerability compared to the parent drug. Furthermore, the best antitumor efficacy was often already reached with doses lower than the maximal tolerated dose, suggesting an improved therapeutic index for the new drug. In conclusion, the results support the preclinical interest of IDN5109 in terms of the toxicity profile and of the efficacy with particular reference to the ability to overcome multiple mechanisms of drug resistance. (+info)
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. (6/4985)6-Hydroxymethylacylfulvene (MGI-114) is a semisynthetic analogue of the toxin illudin S, a product of the Omphalotus mushroom. MGI-114 induces cytotoxicity in a variety of solid tumors in vivo, including the refractory HT29 human colon cancer xenograft. In this study, the potential application of MGI-114 in the treatment of colon cancer was further explored by evaluating the activity of MGI-114 in combination with irinotecan (CPT-11) and 5-fluorouracil (5FU). Groups of 9 nude mice bearing HT29 xenografts were treated with either single agent MGI-114, CPT-11, or 5FU, or MGI-114 in combination with CPT-11 or 5FU. MGI-114 was administered at doses of 3.5 and 7 mg/kg i.p. daily on days 1 through 5, and CPT-11 and 5FU were administered at doses of 50 and 100 mg/kg i.p. on days 1, 12, and 19. In the single agent studies, MGI-114, CPT-11, and 5FU all resulted in decreased final tumor weights compared with vehicle-treated controls (P<0.05), but only MGI-114 at 7 mg/kg produced partial responses. When MGI-114 at 3.5 mg/kg was combined with CPT-11, significant decrements in final tumor weights occurred compared with monotherapy with the same doses of MGI-114 and CPT-11 (P< or =0.001). Also, administration of the low-dose combination (MGI-114 at 35 mg/kg and CPT-11 at 50 mg/kg) resulted in final tumor weights similar to those achieved after administration of high-dose MGI-114 as a single agent. Moreover, the combination of MGI-114 and CPT-11 produced partial responses in nearly all of the animals, with some animals achieving complete responses. The outcome with the combination of MGI-114 and 5FU was less striking, with fewer partial responses and no complete responses. These results suggest enhanced activity when MGI-114 is combined with CPT-11, and clinical trials to further evaluate this combination regimen are planned. (+info)
Cyclosporine inhibited calcium-mediated apoptosis of HL-60 cells. (7/4985)AIM: To study the effects of cyclosporine (Cyc) on apoptosis of HL-60 cells. METHODS: Apoptotic cells induced by harringtonine (Har), camptothecin (Cam), or calcimycin (Cal), thapsigargin (Tha) were identified with DNA electrophoresis, morphology, and flow cytometry. Relative [Ca2+]i alteration of apoptotic HL-60 cells were determined with flow cytometry. RESULTS: Cal 1 mg.L-1 or Tha 0.5 mg.L-1 induced apoptosis of HL-60 cells. This effect was inhibited by nontoxic concentration of Cyc 1 mg.L-1. Cyc did not inhibit Har- or Cam-induced apoptosis of HL-60 cells. Both Cal and Tha increased intracellular calcium, whereas Har or Cam did not. CONCLUSION: Cyc inhibited apoptosis only induced by calcium increasement in HL-60 cells. The mechanism of apoptosis induced by Cal or Tha was different from that by Har or Cam. (+info)
Quercetin induced apoptosis in human leukemia HL-60 cells. (8/4985)AIM: To examine whether quercetin (Que) might induce apoptosis in human leukemia HL-60 cells. METHODS: DNA fragmentation was visualized by agarose gel electrophoresis. Inhibition of proliferation was measured with a colorimetric MTT-assay. The DNA degradation was determined using flow cytometry, and the microscopic changes were observed by an electron microscope. RESULTS: Que 15-120 mumol.L-1 elicited typical apoptosis morphological changes including condensed chromatin, nuclear fragmentation, and reduction in volume. DNA fragmentation and DNA degradation in a concentration-dependent manner in HL-60 cells. Que inhibited HL-60 cell proliferation. The values of IC50 and 95% confidence limits were 43 (30-61) mumol.L-1 after 48-h treatment with Que. CONCLUSION: Que induced apoptosis in HL-60 cells. (+info)
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With...
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab and ramucirumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab and ramucirumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. It is not yet know whether giving cetuximab and irinotecan hydrochloride together is more effective with or without ramucirumab in treating colorectal cancer.. PURPOSE: This randomized phase II trial is studying the side effects and how well giving cetuximab and irinotecan hydrochloride with or without ramucirumab work in treating patients with advanced colorectal cancer with progressive disease after treatment with bevacizumab-containing chemotherapy. ...
Exatecan Mesylate: Proprietary ADC Payload Product Based on BOC Sciences cGMP Platform - India News Magazine
Exatecan Mesylate is a synthetic analog of CPT, which is synthesized to increase solubility and enhance anti-tumor efficacy. The anhydrous, alkali-free form of the drug is called DX-8951. In vitro studies have shown that Exatecan Mesylate is more active than SN-38 and Topotecan on cell lines of various types of human tumors (including breast cancer, lung cancer, gastric cancer, and colon cancer). In the human tumor cloning test, Exatecan Mesylatef showed a dose-dependent inhibitory effect on clonal cells from head and neck, liver, non-small cell lung cancer, breast cancer, colon cancer, ovarian cancer, and prostate cancer. Exatecan Mesylate also has broad activity in human tumor xenografts of breast, lung, gastric, pancreatic, esophageal, and colon cancer, CPT-11-resistant non-small cell lung cancer and pancreatic tumor implanted in nude mice.. Although Exatecan Mesylate has high potency and potential bystander lethality, so far, its relatively challenging biophysical properties may limit ...
Paclitaxel-induced apoptosis may occur without prior G2/M phase arrest :: MEDICA, MUSC Institutional Repository
Paclitaxel (Taxol®) is a member of the taxane class of antineoplastic agents, which has shown great promise in the treatment of a variety of cancers in recent years, including breast, ovarian, head and neck, lung and esophageal carcinomas. Paclitaxel has been shown to cause both mitotic arrest and apoptotic cell death of solid and leukemic tumor cells. Paclitaxel exerts its cytotoxic effects by binding to and inhibiting the depolymerization of intracellular microtubules. This causes the formation of unusually stable microtubules that results in mitotic arrest at the G2iM phase of the cell cycle. However, the biochemical and molecular mechanisms underlying paclitaxel-induced apoptosis, and its relationship with paclitaxel-induced mitotic arrest, are not well described. It is unclear if paclitaxel-induced apoptosis occurs independently of mitotic arrest or if apoptosis is merely a secondary event resulting from G2/M phase arrest. This study investigated the relationship between paclitaxel-induced ...
Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally...
RATIONALE: Drugs used in chemotherapy, such as capecitabine and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy, cetuximab, and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.. PURPOSE: This phase I/II trial is studying the side effects of giving capecitabine and irinotecan hydrochloride together with cetuximab and radiation therapy and to see how well it works in treating patients undergoing surgery for locally advanced rectal cancer. ...
Irinotecan Hydrochloride Trihydrate for Injection by Sandoz Canada Inc. - Uses, Side Effects, Interactions - MedBroadcast.com
Irinotecan Hydrochloride Trihydrate for Injection by Sandoz Canada Inc.: Irinotecan belongs to the group of cancer-fighting medications known as antineoplastics. It kills cancer cells by interfering with the genetic material DNA, which is necessary for their growth and reproduction. Irinotecan is usually used in combination with other medications to treat colon or rectal cancer.
MyJournals.org - Science - DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy (PLoS ONE)
MyJournals.org - Science - DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy (PLoS ONE)
Common Side Effects of Camptosar Injection (Irinotecan Hydrochloride) Drug Center - RxList
Find a comprehensive guide to possible side effects including common and rare side effects when taking Camptosar Injection (Irinotecan Hydrochloride) for healthcare professionals and consumers.
AID 95653 - In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line - PubChem
BioAssay record AID 95653 submitted by ChEMBL: In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line.
Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer | EON:...
Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated
DailyMed - IRINOTECAN HYDROCHLORIDE- irinotecan hydrochloride injection
In the intent-to-treat analysis of the pooled data across all three studies, 193 of the 304 patients began therapy at the recommended starting dose of 125 mg/m2. Among these 193 patients, 2 complete and 27 partial responses were observed, for an overall response rate of 15.0% (95% Confidence Interval [CI], 10.0% to 20.1%) at this starting dose. A considerably lower response rate was seen with a starting dose of 100 mg/m2. The majority of responses were observed within the first two cycles of therapy, but responses did occur in later cycles of treatment (one response was observed after the eighth cycle). The median response duration for patients beginning therapy at 125 mg/m2 was 5.8 months (range, 2.6 to 15.1 months). Of the 304 patients treated in the three studies, response rates to Irinotecan were similar in males and females and among patients older and younger than 65 years. Rates were also similar in patients with cancer of the colon or cancer of the rectum and in patients with single and ...
BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway | PNAS
The data presented in this study suggest an important role for the BAX molecule in the process of chemotherapy-induced apoptosis. This phenomenon was noted in three separate clonal transfectants that overexpressed BAX, making selection artifact unlikely as a cause of the enhanced sensitivity to paclitaxel observed for BAX transfectants. Also, each of the six clones used in this study expressed similar levels of BCL-2 and BCL-xL, which did not change in the presence of paclitaxel, making it unlikely that diminished expression of these molecules is responsible for the observed effect. Interestingly, there was a predominance of BCL-2 compared with BCL-xL in each of the clones used in this study, consistent with previous observations suggesting that an inverse relationship exists between these two proteins in lymphoid cells (24). The fact that none of the lines expressed the MDR-1 protein (p170), a protein known for its ability to mediate paclitaxel resistance through enhanced drug efflux, excludes ...
Oral paclitaxel | Cancer Survivors Network
Interesting phase 3 trial for metastatic breast cancer using a modified oral paclitaxel compared to standard IV paclitaxel every 3 weeks, which found both better response and less neuropathy. I wonder if it will eventually make its way into our world for adjuvant or metastatic treatment!. https://www.ajmc.com/conferences/sabcs-2019/oral-paclitaxel-reveals-superior-confirmed-response-survival-in-patients-with-metastatic-breast-cancer-compared-to-iv-paclitaxel. Tradeoffs were higher neutropenia, infection, and GI size effects (described as low grade and manageable, terms I never really trust), and also fasting apparently. The treatment involves having to fast for 4 hours before taking the encequidar, waiting 1 hour to take the oral paclitaxel, and then waiting 4 hours before eating, with 11 capsules taken in that time frame. They said however that patients were quite compliant due to being excited about avoiding IV therapy.. ...
7-Ethyl-10-HydroxyCamptothecin (SN-38) - Browse fuzing.com to find 7-Ethyl-10-HydroxyCamptothecin (SN-38) sellers, suppliers, wholesalers, companies, manufacturers, exporters, factories.
7-Ethyl-10-hydroxycamptothecin 86639-52-3 properties reference
Guidchem offer qualified suppliers for 7-Ethyl-10-hydroxycamptothecin (CAS NO.86639-52-3) ,Find latest products of 7-Ethyl-10-hydroxycamptothecin manufacturers, suppliers, exporters and producers on guidechem.com.
Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients |...
This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after i.v. infusion of 125 mg/m2 (100 μCi) [14C]CPT-11 in eight patients with solid tumors. Mean ± S.D. recovery of radioactivity in urine and feces was 95.8 ± 2.7% (range 92.2-100.3%, n = 7) of dose. Radioactivity in blood, plasma, urine, and feces was determined for at least 168 h after dosing. Fecal excretion accounted for 63.7 ± 6.8 (range 54.2-74.9%, n = 7) of dose, whereas urinary excretion accounted for 32.1 ± 6.9% (range 21.7-43.8%; n = 7) of dose. One patient with a biliary T-tube excreted 30.1% of dose in bile, 14.2% in feces, and 48.2% in urine. Quantitative radiometric HPLC revealed that CPT-11 was the major excretion product in urine, bile, and feces. Aminopentane carboxylic acid (APC) and SN-38 glucuronide (SN-38G) were the most significant metabolites in urine and bile, whereas SN-38 and NPC, a primary amine metabolite, were relatively minor excretion products. SN-38 and APC were the most ...
Paclitaxel best suppliers/vendors - Labshake
Paclitaxel best suppliers; Paclitaxel best sources; Paclitaxel best vendors; Paclitaxel protocol; Paclitaxel citations; Paclitaxel publications; Paclitaxel papers - Labshake
Cheap Etoposide 50mg Order Online - Etoposide Purchase No Prescriptions » South Wedding Dreams Social Network - Welcome to the...
Cheap Etoposide 50mg Order Online - Etoposide Purchase No Prescriptions. Cheap Etoposide 50mg Order Online - Etoposide Purchase No PrescriptionsCheap Etoposide Import. Buy Etoposide Online Classic. Buying Etoposide Canada OnlineOrder Etoposide 50mg SafelyBUY Etoposide (Vepesid) ONLINE! - CLICK HERE!etoposide buy to canadabuy etoposide drugsetoposide farmacia comprarcheap etoposide 50 mg tab ukis it safe to buy etoposide from canadavepesid order discountetoposide cheap europebuying vepesid austra
Events & Presentations | Athenex, Inc.
Abstract title: Oral Paclitaxel with Encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: a Phase III clinical study in metastatic breast ...
Is an anticancer drug helping cancer to spread?
New research shows how the side effects of the common chemotherapy drug paclitaxel may cause cancer to spread from the breast to the lungs.
Drug Interactions With Omacetaxine
This eMedTV selection explains how potentially serious side effects or other dangerous complications may occur when omacetaxine is combined with certain drugs. Other interactions are described in this article, along with ways to avoid problems.
SYNRIBO (omacetaxine mepesuccinate) | Healthcare Professional Site
Learn more about SYNRIBO (omacetaxine mepesuccinate) for Injection, for subcutaneous use, including indication, treatment, safety information, and MOA.
Irinotecan Liposomal (Onivyde) | Daviss Drug Guide
Find information on Irinotecan Liposomal (Onivyde) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
Paclitaxel - Paclitaxel - Aventis
Paclitaxel is mainly associated with symptoms and indications-The International Classification of Diseases (ICD)- L01CD01-Paclitaxel ...
Paclitaxel released from a self-assembling supramolecul | Open-i
Paclitaxel released from a self-assembling supramolecule in the presence of the MMP-2 enzyme. Various complexes of peptides and paclitaxel (paclitaxel 100 μg)
Docetaxel, What is Docetaxel? About its Science, Chemistry and Structure
Find out about the science and chemistry of Docetaxel (Taxotere), see colourful images of Docetaxel and explore interactive 3D molecules of Docetaxel
Paclitaxel is a medicine prescribed for treating lung cancer, breast cancer, and ovarian cancer. This eMedTV resource describes paclitaxel uses in more detail, explains how the medication works, and offers general dosing information.
Paclitaxel is a medicine prescribed for treating lung cancer, breast cancer, and ovarian cancer. This eMedTV resource describes paclitaxel uses in more detail, explains how the medication works, and offers general dosing information.
PubPeer - Low concentrations of paclitaxel induce cell type-dependent...
There are comments on PubPeer for publication: Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity (2001)
PACLITAXEL ACCORD 6 mg/ml koncentr tum oldatos inf zi hoz
1. MILYEN T PUS GY GYSZER A PACLITAXEL ACCORD S MILYEN BETEGS GEK ESET N ALKALMAZHAT Az n gy gyszer nek neve Paclitaxel Accord 6 mg/ml, koncentr tum oldatos
Biomedis Paclitaxel - Drugs.com
Biomedis Paclitaxel is a medicine available in a number of countries worldwide. A list of US medications equivalent to Biomedis Paclitaxel is available on the Drugs.com website.
Paclitaxel, |99.5% | LC Laboratories
Paclitaxel, |99.5%, CAS#33069-62-4, More than 1,250 labs worldwide have purchased Paclitaxel from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
Irinotecan is a chemotherapy drug that is given as a treatment for some types of cancer. It is most commonly used to treat bowel cancer...
example of paclitaxel comprising stable nanocomposition
Page contains details about example of paclitaxel comprising stable nanocomposition . It has composition images, properties, Characterization methods, synthesis, applications and reference articles : nano.nature.com
Etoposide Pharmaswiss - Drugs.com
Etoposide Pharmaswiss is a medicine available in a number of countries worldwide. A list of US medications equivalent to Etoposide Pharmaswiss is available on the Drugs.com website.
example of docetaxel comprising stable nanocomposition
Page contains details about example of docetaxel comprising stable nanocomposition . It has composition images, properties, Characterization methods, synthesis, applications and reference articles : nano.nature.com
5 essential rules for ripped abs
Forget inconvenient diets and three-hour gym sessions. Score the six-pack abs and body youve always wanted by following these better, smarter rules.
Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint<...
TY - JOUR. T1 - Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint. AU - Sudo, Tamotsu. AU - Nitta, Masayuki. AU - Saya, Hideyuki. AU - Ueno, Naoto T.. PY - 2004/4/1. Y1 - 2004/4/1. N2 - Paclitaxel stabilizes microtubules, causing mitotic arrest and activating the spindle assembly checkpoint. We determined whether suppression of the checkpoint genes Mad2 and BubR1 affects paclitaxel resistance and whether overexpression of Mad2 protein in checkpoint-defective cells enhances paclitaxel sensitivity. Suppression of Mad2 and BubR1 in paclitaxel-treated cancer cells abolished checkpoint function, resulting in paclitaxel resistance that correlated with suppression of cyclin-dependent kinase-1 activity. In contrast, overexpression of Mad2 in cells with a checkpoint defect attributable to low Mad2 expression restored checkpoint function, resulting in enhanced paclitaxel sensitivity that correlated with enhanced cyclin-dependent kinase-1 activity. However, overexpression of ...
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. - Nuffield Department of...
BACKGROUND: Less than 50% of ovarian cancers respond to paclitaxel. Effective strategies are needed to enhance paclitaxel sensitivity. METHODS: A library of silencing RNAs (siRNAs) was used to identify kinases that regulate paclitaxel sensitivity in human ovarian cancer SKOv3 cells. The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. All statistical tests were two-sided. RESULTS: Src family and Abl kinases were identified as modulators of paclitaxel sensitivity in SKOv3 cells. The siRNA knockdown of Src, Fyn, or Abl1 enhanced paclitaxel-mediated growth inhibition in ovarian cancer cells compared with a control
A Ramberg-Backlund route to the stilbenoid anti-cancer agents combretastatin A-4 and DMU-212 - Research Database, The...
A concise route to combretastatin A-4, a potent inhibitor of tubulin polymerisation, using a Ramberg-Backlund reaction to form the key (Z)-stilbene unit has been developed; this Ramberg-Backlund approach has also been extended to prepare the (E)-stilbene DMU-212, which also possesses interesting growth inhibitory properties. ...
Resistance to Paclitaxel Is Proportional to Cellular Total Antioxidant Capacity | Cancer Research
In this study, evidence has been collected that supports the notion that paclitaxel may exert its toxicity via elevation of intracellular O2−, H2O2, and NO levels. This theory is confirmed by our data showing that (a) paclitaxel induced the production of O2−, H2O2 and NO; (b) paclitaxel induced oxidative DNA damage; (c) agents that decreased H2O2 and NO production suppressed paclitaxel-induced DNA damage, G2-M arrest, apoptosis, and cell growth inhibition; (d) inhibition of SOD or glutamylcysteine synthase increased paclitaxel-induced apoptosis; (e) cell lines with higher total antioxidant capacity were more resistant to paclitaxel cytotoxicity; and (f) agents that decreased clonogenic survival in paclitaxel-treated cells also decreased cellular total antioxidant capacity. Thus, paclitaxel chemoresistance correlates very well to intracellular antioxidant capacity.. Kong et al. ( 27) speculated that many chemotherapeutic agents exert their toxic effects on cancer cells by producing free ...
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab with or without Eflornithine in Treating Patients with Relapsed or...
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab with or without Eflornithine in Treating Patients with Relapsed or Refractory Neuroblastoma - NCT03794349
FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines
Paclitaxel is used to treat breast cancers, but the mechanisms by which it induces apoptosis are poorly understood. Consequently, we have studied the role of the FoxO transcription factors in determining cellular response to paclitaxel. Western blotting revealed that in a panel of nine breast cancer cell lines expression of ... read more FoxO1a and FoxO3a correlated with the expression of the pro-apoptotic FoxO target Bim, which was associated with paclitaxel-induced apoptosis. In MCF-7 cells, which were paclitaxel-sensitive, the already high basal levels of FoxO3a and Bim protein increased dramatically after drug treatment, as did Bim mRNA, which correlated with apoptosis induction. This was not observed in MDA-231 cells, which expressed low levels of FoxOs and Bim. Gene reporter experiments demonstrated that in MCF-7 cells maximal induction of Bim promoter was dependent on a FoxO binding site, suggesting that FoxO3a is responsible for the transcriptional up-regulation of Bim. Gene silencing ...
Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields...
Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls. ST. HELIER, Jersey-(BUSINESS WIRE)- Novocure (NASDAQ: NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology. The INNOVATE trial was a prospective, single-arm study testing the feasibility, safety and preliminary efficacy of Tumor Treating Fields combined with weekly paclitaxel in recurrent ovarian cancer. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. Progression free survival of recurrent ovarian cancer patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls. A clear unmet need remains for patients with recurrent ovarian cancer, ...
Gemcitabine resistant pancreatic cancer cells are sensitive to paclitaxel treatment - Amsterdam UMC - Vrije Universiteit...
TY - CONF. T1 - Gemcitabine resistant pancreatic cancer cells are sensitive to paclitaxel treatment. AU - Le Large, TYS. PY - 2017. Y1 - 2017. M3 - Poster. ER - ...
Paclitaxel, a chemotherapy drug frequently used to treat a range of cancers, is considered a microtubule inhibitor that arrests tumor cells in mitosis, but concentrations that have been used in cell culture to characterize the mechanism of action may be much higher than intratumoral concentrations. To determine clinically relevant paclitaxel concentrations in breast cancer, Zasadil and colleagues enrolled 6 patients in a clinical trial in which intratumoral paclitaxel levels and mitotic status were evaluated before and 20 hours after infusion with neoadjuvant paclitaxel, and tumor response was evaluated after 3 additional standard cycles of paclitaxel therapy. Interestingly, in 5 evaluable patients, mitotic arrest did not correlate with tumor regression. Concentrations of paclitaxel deemed clinically relevant based on levels in patient plasma and tumor samples 20 hours after initial infusion remained sufficient in inducing cell death in breast cancer cell lines but did so by increasing the ...
Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance<...
TY - JOUR. T1 - Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. AU - Khongkow, P.. AU - Gomes, A. R.. AU - Gong, C.. AU - Man, E. P.S.. AU - Tsang, J. W.H.. AU - Zhao, F.. AU - Monteiro, L. J.. AU - Coombes, R. C.. AU - Medema, R. H.. AU - Khoo, U. S.. AU - Lam, E. W.F.. PY - 2016/2/25. Y1 - 2016/2/25. N2 - All rights reserved. FOXM1 has been implicated in taxane resistance, but the molecular mechanism involved remains elusive. In here, we show that FOXM1 depletion can sensitize breast cancer cells and mouse embryonic fibroblasts into entering paclitaxel-induced senescence, with the loss of clonogenic ability, and the induction of senescence-associated β-galactosidase activity and flat cell morphology. We also demonstrate that FOXM1 regulates the expression of the microtubulin-associated kinesin KIF20A at the transcriptional level directly through a Forkhead response element (FHRE) in its promoter. Similar to FOXM1, KIF20A expression ...
CAMPTOSAR® (irinotecan HCl) Clinical Pharmacology | Información Médica de Pfizer - Peru
Irinotecan serves as a water-soluble precursor of the lipophilic metabolite SN-38. SN-38 is formed from irinotecan by carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the dipiperidino side chain. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumor cell lines. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold; however, the plasma area under the concentration versus time curve (AUC) values for SN-38 are 2% to 8% of irinotecan and SN-38 is 95% bound to plasma proteins compared to approximately 50% bound to plasma proteins for irinotecan [see Clinical Pharmacology (12.3)]. The precise contribution of SN-38 to the activity of CAMPTOSAR is thus unknown. Both irinotecan and SN-38 exist in an active lactone form and an inactive hydroxy acid anion form. A pH-dependent equilibrium exists between the two forms such that an ...
RePub, Erasmus University Repository: Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of...
Preclinical data suggests that protein and calorie restriction (PCR) might improve treatment tolerability without impairing antitumor efficacy. Therefore, we have studied the influence of PCR on irinotecan pharmacokinetics and toxicity. In this crossover trial, patients with liver metastases of solid tumors were included and randomized to treatment with irinotecan preceded by 5 days of PCR (~ 30% caloric and ~ 70% protein restriction) during the first cycle and a second cycle preceded by a normal diet or vice versa. Pharmacokinetic blood sampling and biopsies of both healthy liver and liver metastases were performed. The primary end point was the relative difference in geometric means for the active metabolite SN-38 concentration in healthy liver analyzed by a linear mixed model. No significant differences were seen in irinotecan (+ 16.8%, P = 0.22) and SN-38 (+ 9.8%, P = 0.48) concentrations between PCR and normal diet in healthy liver, as well as in liver metastases (irinotecan: −38.8%, P = ...
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian...
The primary purpose of this study was to evaluate the effect of CYP2C8*3 and three genetic ABCB1 variants on the elimination of paclitaxel. We studied 93 Caucasian women with ovarian cancer treated with paclitaxel and carboplatin. Using sparse sampling and nonlinear mixed effects modeling, the individual clearance of unbound paclitaxel was estimated from total plasma paclitaxel and Cremophor EL. The geometric mean of clearance was 385 l h(-1) (range 176-726 l h(-1)). Carriers of CYP2C8*3 had 11% lower clearance than non-carriers, P = 0.03. This has not been shown before in similar studies; the explanation is probably the advantage of using both unbound paclitaxel clearance and a population of patients of same gender. No significant association was found for the ABCB1 variants C1236T, G2677T/A and C3435T. Secondarily, other candidate single-nucleotide polymorphisms were explored with possible associations found for CYP2C8*4 (P = 0.04) and ABCC1 g.7356253C andgt; G (P = 0.04).. ...
Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure
Combretastatin-A4 disodium phosphate (CA4DP) is a vascular-disruptive agent that causes an abrupt decrease in tumor blood flow. The direct actions of CA4DP include increases in vascular permeability and destabilization of the endothelial cytoskeleton, which are thought to contribute to occlusion of …
The immunomodulator PSK induces in vitro cytotoxic activity in tumor cell lines via arrest of cell cycle and induction of...
These results indicate that PSK has cytotoxic activity in vitro on tumor cell lines. This new cytotoxic activity of PSK on tumour cells is independent of its
Peptinovo | Our Solution
PNB-281 is a novel, ultra-small nanoparticle loaded with a fatty derivative of the world-leading cancer drug paclitaxel to enable greater efficacy without neuropathy. Over 70% of the patients treated with the approved paclitaxel formulations, Taxol® or Abraxane®, experience paclitaxel-induced peripheral neuropathy (PIPN). In some, the symptoms are severe and require dose cutbacks or premature end of dosing, which risk treatment failure. To make matters worse, the pain, tingling, numbness, and weakness of PIPN in the extremities typically persist well after treatment has ended, often for months and even years, further degrading quality of life and safety. PNB-281 is designed to keep paclitaxel away from nerves, and instead deliver it to the tumors it is intended to kill. This is accomplished by chemically linking paclitaxel to a fat and embedding it in a peptide-amphiphile lipid micelle (PALM) that is captured by a receptor found to be abundant in cancer cells but not in nerves. PALM is a mimic ...
The paclitaxel vehicle CrEL has been shown to influence the toxicity, pharmacokinetics, and antitumor activity of paclitaxel (2, 3, 4, 5 , 6, 7, 8 , 10, 11, 12, 13) . With regard to paclitaxel-induced HSR, CrEL is probably responsible, because other drugs formulated with it produce similar reactions, and CrEL-free paclitaxel does not cause HSR. Likewise, a growing body of evidence shows that CrEL itself is closely related with peripheral neuropathy, one of the main side effects reported for paclitaxel chemotherapy (28, 29, 30) . The CrEL concentrations achieved by therapeutic doses of paclitaxel have been shown to produce axonal swelling, vesicular degeneration, and demyelination in vivo (31) . Similarly, peripheral neuropathy is more augmented in short infusion because CrEL clearance increases by extending the infusion duration from 3 to 24 h (32) . Besides these issues, CrEL-formulated vehicle is associated with pharmacokinetic paclitaxel alterations. CrEL has been shown to cause nonlinear ...
paclitaxel chemotherapy side effects<...
Doctors often recommend chemotherapy as a treatment for cancer. Chemotherapy uses drugs that kill dividing cancer cells and prevent them from growing. Many chemotherapy drugs ...
Transposases in Etoposide Resistance - Robert Hromas
Transposase activity was thought to be extinct in humans because DNA movement can be deleterious in higher organisms, resulting in genomic instability and perha...
A phase II randomised study comparing the clinical benefit between Paclitaxel (Taxol) and oral Vinorelbine (Navelbine) in...
This study compared the efficacy and tolerability of monotherapy with paclitaxel [Taxol] versus vinorelbine [Navelbine] as first-line therapy in patients with
This study was performed to explore the influence of alternate sequences of CPT-11 and CDDP on the observed side effects and pharmacokinetic behavior of both drugs. Using a randomized cross-over design for the administration sequence, no substantial differences in any toxicity were observed between the two treatment schedules. The pharmacokinetics of the lactone form of CPT-11 revealed a substantial degree of interpatient variability, in line with previous observations (17) . In addition, the observed kinetic parameters of CPT-11 were similar to single agent data (18) , indicating no apparent interaction between CDDP and CPT-11. The sequence of drug administration had also no influence on the pharmacokinetics of CPT-11 and its metabolites SN-38 and SN-38G and the CYP450 3A4-mediated metabolites APC and NPC at the dose levels administered. This contrasts the reduction of topotecan clearance observed previously in patients after CDDP administration (5) . Our findings, however, are consistent with ...
13 | November | 2013 | Boobs of Steel
Tomorrow will be 5 weeks since my last infusion.. During my 8-week course of the dose-dense A/C, I gained an additional 14 pounds, on top of my already 50 pounds of excess baggage. That was in spite of feeling so much like crap that I rarely ate. After two weeks off from chemo, I noticed I was losing almost a pound of weight per day, so that by the time I started the weekly paclitaxel infusions, I was back to my starting weight.. Then the scale crept up, up, up, again, until I was an additional 27 pounds. I didnt worry much about it. I thought it would start peeling off again when I was through with the paclitaxel. I couldnt wear my wedding ring, and I cant wear most of my clothes, but hey! Its temporary, right? Hmm. A two week break from paclitaxel, and no downward movement on the scale. I dont think I can blame all this weight gain on the steroid any more, and I said as much to my chemo nurse when I went back on the paclitaxel.. However, today, despite not having changed a thing, my ...
Taxol - Chemotherapy Drugs - Chemocare
Taxol (Paclitaxel) chemotherapy side effects, how its given, how it works, precaution and self care tips for treatment of multiple cancers
Paclitaxel Market 2019 | Detailed Insights Of The Market With Competitive Analysis And Forecasts To 2027 - Financial Sector
Paclitaxel Market Report includes investigations based on Current scenarios, Historical records, and future predictions. An accurate data of various aspects such as Type, Size, Application, and end-user have been scrutinized in this research report. It presents the 360-degree overview of the competitive landscape of the industries. SWOT analysis has been used to understand the Strength, Weaknesses, bussiness Opportunities, and threats in front of the businesses. Thus, helping the companies to understand the threats and challenges in front of the businesses. Paclitaxel Market is showing steady growth and CAGR is expected to improve during the forecast period.. The Paclitaxel report presents an estimation of the forecast from 2019 to 2027 and market history from 2014 to 2018. The information provided in the form of earnings likely to be produced in (USD xx million) year to year by Paclitaxel growth rate (CAGR).. ...
paclitaxel protein-bound - description, side Effects of paclitaxel protein-bound, dosage (paclitaxel protein-bound), proper use of paclitaxel protein-bound. Drugs review.
Paclitaxel Protein-Bound - description, side Effects of Paclitaxel Protein-Bound, dosage (Paclitaxel Protein-Bound), proper use of Paclitaxel Protein-Bound. Drugs review.
Paclitaxel - Paclitaxel Manufacturer, Supplier & Exporter
Find here paclitaxel manufacturers, paclitaxel dealers, suppliers, traders & exporters. Listed manufacturing companies are offering wide range of paclitaxel with price, rating & reviews.
Intravenous methadone for severe pain in children with cancer
We describe the effect and side effects in two children with cancer treated with intravenous methadone due to vincristine-induced neuropathy.
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With...
This trial compared the efficacy, pharmacokinetics, pharmacodynamics and tolerability of paclitaxel alone and in combination with LCL 161 [Novartis] in patients
Preclinical pharmacokinetic models capable of predicting concentrations/exposure in vivo under different dosing schema can provide an invaluable tool for the rational design of clinical dosing protocols. The overall goals of the studies described herein were to design and evaluate the use of rational dosing protocols for vandetanib, docetaxel, and combinations of the two using pharmacokinetically directed dosing protocols that were reflective of exposures attainable in humans and that target antitumor and antiangiogenic responses. We utilized a PBPK model for docetaxel to develop dosing protocols that would allow us to examine the effects of standard docetaxel treatment versus a metronomic or antiangiogenic schedule of docetaxel. Pharmacokinetic data on vandetanib was used to determine a steady-state dose level that was reflective of human vandetanib exposure (32).. Preclinical testing is an integral part of the development of new therapeutics and new therapeutic strategies. With increasing ...
Generic Paclitaxel for Different Types of Cancer
Paclitaxel drug is used for treating various types of cancers like breast cancer, ovarian cancer, lung cancer and certain types of skin cancers.
Buy Irinotecan 40/100mg Liquid Injection: Uses, Side Effects
Buy Irobenz (Irinotecan) injection, used as a chemotherapy agent against a variety of solid tumors, such as colorectal, pancreatic, ovarian, and lung cancers.
Search Articles | University of Toronto Libraries
Cardiovascular diseases are the most common cause of death among the elderly in the Western world. Resveratrol (3,5,4′‐trihydroxystilbene) is a plant‐derived ...
Savita Halappanavar inquest: Three-hour delay in sending vital blood sample for testing - BelfastTelegraph.co.uk
A vital blood sample that would have flagged the seriousness of Savita Halappanavars condition earlier was not sent to the lab for three hours.
onderhoudstherapie met vinorelbine en continue lage dosis cyclofosfamide vergeleken met stoppen bij patiënten met hoog-risico...
onderhoudstherapie met vinorelbine en continue lage dosis cyclofosfamide vergeleken met stoppen bij patiënten met hoog-risico rhabdomyosarcoom geeft betere 5-jaars overall overleving 86 vs 74 procent. Artikel geplaatst 7 oktober 2019
Cisplatin, antineoplastic agent (CAS 15663-27-1) (ab141398) | Abcam
MW 300.05. Potent, broad spectrum antineoplastic agent. Achieve your results faster with highly validated, pure and trusted compounds.
Global Paclitaxel Injection Market Professional Survey Report 2017
Paclitaxel Injection market report added by qyresearchgroups.com. In this Report includes best market price, trends, Growth, Forecast, Analysis, demand & Overview.
Global Paclitaxel Market Status Forecast: Ken Research
The report forecast global Paclitaxel market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2024...
List of MeSH codes (D27)
... antineoplastic agents, hormonal MeSH D27.505.954.248.179 - antineoplastic agents, phytogenic MeSH D27.505.954.248.589 - ... antineoplastic MeSH D27.505.954.248.147 - antimitotic agents MeSH D27.505.954.248.150 - antineoplastic agents, alkylating MeSH ... MeSH D27.505.519.124 - alkylating agents MeSH D27.505.519.124.035 - antineoplastic agents, alkylating MeSH D27.505.519.155 - ... lipotropic agents MeSH D27.505.954.248 - antineoplastic agents MeSH D27.505.954.248.025 - angiogenesis inhibitors MeSH D27.505. ...
Antineoplastic Agents, Phytogenic - DrugBank
Antineoplastic Agents, Phytogenic. Accession Number. DBCAT000717. Description. Agents obtained from higher plants that have ... A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary ... A cytotoxic agent used for the removal of soft genital (venereal) warts (condylomata acuminata).. ... A topical agent used for the treatment of external genital warts and perianal warts. ...
Search of: 'Endodermal Sinus Tumor' | 'Antineoplastic Agents, Phytogenic' - List Results - ClinicalTrials.gov
Search of: 'Ovarian Germ Cell Cancer' | 'Antineoplastic Agents, Phytogenic' - List Results - ClinicalTrials.gov
Explore the British Library Search - Antineoplastic Agents, Phytogenic
Antineoplastic Agents, Phytogenic | The Chopra Library
Mannidex - Antimitotic agent, Antineoplastic Agents, Phytogenic, Keratolytic Agents
... has role antineoplastic agent (CHEBI:35610) rotenone (CHEBI:28201) has role metabolite (CHEBI:25212) ... rotenone (CHEBI:28201) has role phytogenic insecticide (CHEBI:22917) rotenone (CHEBI:28201) has role toxin (CHEBI:27026) ... antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. ...
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients - Full Text View - ClinicalTrials.gov
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors - Full Text View -...
Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 - Full Text View -...
Fast atom bombardment mass spectrometry of bouvardin and selected analogs
Ginger's (Zingiber officinale Roscoe) inhibition of rat colonic adenocarcinoma cells proliferation and angiogenesis in vitro
RCSB PDB - VLB Ligand Summary Page
RCSB PDB - EVP Ligand Summary Page
Antineoplastic Agents. *Antineoplastic Agents, Phytogenic. *Antineoplastic and Immunomodulating Agents. *BCRP/ABCG2 Substrates ... Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It ... For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line ...
Antineoplastic Agents, Phytogenic. *Humans. *Medicine, Ayurvedic. *Neoplasms. *Plants, Medicinal. Notes:. * An integrated ... injectable agents, such as botox, fibrel, autologous fat grafting as also few surgical procedures have been used. Ayurveda, the ... injectable agents, such as botox, fibrel, autologous fat grafting as also few surgical procedures have been used. Ayurveda, the ...
Characterization of thiol-conjugated metabolites of ginger components shogaols in mouse and human urine and modulation of the...
Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt...
Antineoplastic Agents, Phytogenic / pharmacology*. Apoptosis / drug effects*. Cell Cycle / drug effects. Cell Proliferation / ... 0/Antineoplastic Agents, Phytogenic; 0/CCND1 protein, human; 0/CDKN1B protein, human; 0/FOXO3 protein, human; 0/Forkhead ... it is this quality that often makes them desirable as chemotherapeutic agents against cancer [17,41,48-50]. Studies in both in ... suggesting its potential role as a chemotherapeutic agent.. ...
MEDLINE - Resultado p gina 1
0 (Antineoplastic Agents, Phytogenic); 0 (Naphthoquinones); EC 220.127.116.11 (TOR Serine-Threonine Kinases); EC 18.104.22.168 ( ... 0 (Antineoplastic Agents, Phytogenic); 0 (Naphthoquinones); 0 (Protein Kinase Inhibitors); 106441-73-0 (Osteopontin); EC 2.7. ... Plumbagin shows antineoplastic effects via multi-channel molecular mechanisms, including the induction of apoptosis and ...
MEDLINE - Resultado p gina 1
0 (Alkaloids); 0 (Anti-Inflammatory Agents); 0 (Antineoplastic Agents, Phytogenic); 0 (Indolizines); 0 (Lipopolysaccharides); 0 ... 0 ((13aS)-deoxytylophorinine); 0 (Alkaloids); 0 (Antineoplastic Agents, Phytogenic); 0 (Indolizidines); 0 (Intercalating Agents ... 0 (Alkaloids); 0 (Antineoplastic Agents, Phytogenic); 0 (Indolizines); 0 (Nucleic Acids); 0 (Phenanthrenes); 0 (Phenanthrolines ... 0 (ATF1 protein, human); 0 (Activating Transcription Factor 1); 0 (Alkaloids); 0 (Antineoplastic Agents, Phytogenic); 0 (CCNA2 ...
Analysis of antiproliferative effect of Chamerion angustifolium water extract and its fractions on several breast cancer cell...
A new cytotoxic amide from the stem wood of Hibiscus tiliaceus. - NextBio article
Research Faculty - Last Initial D - Wake Forest School of Medicine
TDM1 trial (KATHERINE) Phase III - HER2 Support Group Forums
The effect of seal oil on paclitaxel induced cytotoxicity and apoptosis in breast carcinoma MCF-7 and MDA-MB-231 cell lines. |...
3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a...
Embryonal Sarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
Malignant Epithelial Mesothelioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
Polysaccharide aus Nerium oleander: Struktur und biologische Aktivität [Polysaccharides from Nerium oleander: structure and...
Translational activation in T-ALLa-c) Diagram of muta | Open-i
- Plumbagin shows antineoplastic effects via multi-channel molecular mechanisms, including the induction of apoptosis and autophagy, the disruption of the cell cycle, the inhibition of invasion and metastasis, and anti-angiogenesis. (bireme.br)
- Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. (openrepository.com)
- Selection of the 50 genes best correlated with 5-FU-induced apoptosis, but not 50 randomly selected genes, significantly predicted response to this agent. (edu.au)
- Furthermore, reanalysis of the database demonstrated that selection of the 149 genes best correlated with CPT-induced apoptosis maximally and significantly predicted response to this agent. (edu.au)
- This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (nih.gov)
- Therefore, oleanolic acid may be used as a therapeutic agent in the treatment of human HCC. (nih.gov)
- Our study is the first to report that TPs inhibit GBC cell growth and these compounds may have potential as novel therapeutic agents for treating gallbladder cancer. (bvsalud.org)
- These results support a potential therapeutic role of radiolabeled hu3S193 in the treatment of breast cancer, including combination therapy with Taxol, and warrants further investigation of this promising new agent. (edu.au)
- 9. continued) Patients who receive irinotecan for non-therapeutic purposes unrelated to this study (such as presurgically for obtaining pharmacology data for the agent) will be eligible to enter the study provided they have recovered from the toxic effects of the agent if any. (comparetrials.com)
- Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-tumour effects of zoledronic acid. (ox.ac.uk)
- A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer. (drugbank.ca)
- Antisense oligonucleotide (ASO)-induced down-regulation of XIAP is effective at inducing cell death and delaying the growth of adult tumour cells as xenografts and these agents are currently in phase II clinical trials. (openrepository.com)
- Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (uconn.edu)
- The EC50 value of some of the alkaloids was in the low nanomolar range, comparable to that of the clinically used antineoplastic drug doxorubicin. (bireme.br)
- Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. (nel.edu)
- Patients must have recovered from the toxic effects of prior therapy: 4 weeks from any investigational agents, two weeks from vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, cis-retinoic acid, etc. (radiosensitizer does not count). (comparetrials.com)
- These patients had been treated with single-agent or combination chemotherapy either in the context of clinical trials or outside trials according to standard HeCOG protocols. (uoi.gr)
- Docetaxel is one of the most effective chemotherapeutic agents in the treatment of breast cancer. (elsevier.com)
- Fragmentation pathways are postulated which account for most of the major ions observed in the FAB mass spectra of these potentially useful antitumor agents. (nih.gov)
- The combination of certain MDR1/MRP1 substrate drugs with O6-alkylating agents (against which MGMT confers resistance) is particularly myelotoxic. (openrepository.com)
- Alkylating agents can be detoxified by conjugation with glutathione (GSH). (tudelft.nl)
- One of the physiological significances of this lies in the observation that cancer cells resistant to the cytotoxic effects of alkylating agents have higher levels of GSH and high glutathione S-transferase (GST) activity. (tudelft.nl)
- However, little is known about the GSH-/GST-dependent biotransformation of alkylating agents, including cyclophosphamide. (tudelft.nl)
- Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (drugbank.ca)
- Tumour resistance to chemotherapeutic agents results in most chemotherapy being administered in a multi-agent fashion that is often associated with a high level of toxicity in highly proliferative tissues such as the haematopoietic compartment. (openrepository.com)
- Among these, lanosterol (1), inotodiol (3), lanost-8,24-diene-3β,21-diol (4), and trametenolic acid (5) demonstrated proproliferative effects on HFDPCs more potent than minoxidil, an anti-alopecia agent, used as the positive control. (tokushima-u.ac.jp)
- Thus, whilst many genetic manipulation strategies aim to protect normal tissue against a single component of a multi-agent regime, it is clearly preferable to protect normal cells against all toxicities. (openrepository.com)
- These studies demonstrate that the basal gene expression profile of colon cancer cells can be used to predict and distinguish response to multiple chemotherapeutic agents and establish the potential of this methodology as a means by which rational decisions regarding choice of therapy can be approached. (edu.au)
- Lanostane-type triterpnes from the sclerotium of Inonotus obliquus (Chaga mushrooms) as proproliferative agents on human follicle dermal papilla cells, Journal of Natural Medicines, Vol.73, No.3, 597-601, 2019. (tokushima-u.ac.jp)
- Our finding suggests that EERFB is an agent that may have antioxidant activity and inhibit the growth of cancer cells. (nchu.edu.tw)